BT-11 is primarily used in the field of medical research, particularly in the development of treatments for autoimmune diseases. It functions as a selective modulator of the immune system, helping to regulate immune responses that are often overactive in conditions like inflammatory bowel disease (IBD) and multiple sclerosis. By targeting specific pathways involved in inflammation, BT-11 aims to reduce symptoms and improve patient outcomes without broadly suppressing the immune system, which is a common drawback of traditional therapies. Its potential to offer a more targeted and safer treatment option makes it a promising candidate in ongoing clinical trials.